Evidence map›Paper›PMID 30864317›Full record

ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2019

PLATYPUS: A Multiple-View Learning Predictive Framework for Cancer Drug Sensitivity Prediction.

Kiley Graim, Verena Friedl, Kathleen E Houlahan, Joshua M Stuart

Abstract read
In one paragraph

Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kiley GraimDept. of Biomolecular Engineering, University of California, Santa Cruz, CA 95064, USA*Currently at the Flatiron Institute & Princeton University.
Verena Friedl
Kathleen E Houlahan
Joshua M Stuart

Funding

Pharmaco Response Signatures and Disease MechanismU54HL127365 · NHLBI · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2014 to 2019
$13.1M
Pharmaco Response Signatures and Disease MechanismU54HG006097 · NHGRI · HARVARD MEDICAL SCHOOL · PI MITCHISON, TIMOTHY J, SORGER, PETER KARL · 2010 to 2013
$9.7M
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)U24CA143858 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI BENZ, CHRISTOPHER, HAUSSLER, DAVID H · 2009 to 2016
$8.9M
BIGDATA: Mid-Scale DCM: DA: ESCE: Discovering Molecular ProcessesR01CA180778 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STUART, JOSHUA MICHAEL · 2013 to 2017
$3.5M
New Integrative Pathway Analysis Methods to Predict Biomedical OutcomesR01GM109031 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STUART, JOSHUA MICHAEL · 2014 to 2018
$2.9M
UCSC-Buck Specialized Genomic Data Analysis Center for the Genomic Data Analysis NetworkU24CA210990 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STUART, JOSHUA MICHAEL · 2016 to 2020
$2.2M
NCI NIH HHS R01 CA180778NCI NIH HHS U24 CA143858NCI NIH HHS U24 CA210990NHGRI NIH HHS U54 HG006097NHLBI NIH HHS U54 HL127365NIGMS NIH HHS R01 GM109031
6 · The paper itself

Abstract

Cancer is a complex collection of diseases that are to some degree unique to each patient. Precision oncology aims to identify the best drug treatment regime using molecular data on tumor samples. While omics-level data is becoming more widely available for tumor specimens, the datasets upon which computational learning methods can be trained vary in coverage from sample to sample and from data type to data type. Methods that can 'connect the dots' to leverage more of the information provided by these studies could offer major advantages for maximizing predictive potential. We introduce a multi-view machinelearning strategy called PLATYPUS that builds 'views' from multiple data sources that are all used as features for predicting patient outcomes. We show that a learning strategy that finds agreement across the views on unlabeled data increases the performance of the learning methods over any single view. We illustrate the power of the approach by deriving signatures for drug sensitivity in a large cancer cell line database. Code and additional information are available from the PLATYPUS website https://sysbiowiki.soe.ucsc.edu/platypus.

Indexed as

Drug Resistance, NeoplasmMachine LearningAntineoplastic AgentsCell Line, TumorComputational BiologyDatabases, FactualHumansInformation Storage and RetrievalNeoplasmsPatient-Specific ModelingPharmacogenomic VariantsPrecision MedicineSoftwareSupervised Machine LearningAntineoplastic Agents

Identifiers

PMID30864317
PMCPMC6417802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.